Evidence map›Paper›PMID 38837091›Full record

ArticleNeurochemical research2024

A Perspective on the Characterization of Early Neural Progenitor Cell-Derived Extracellular Vesicles for Targeted Delivery to Neuroblastoma Cells.

Oğuz Kaan Kırbaş, Batuhan Turhan Bozkurt, Melis Rahime Yıldırım, Pakize Neslihan Taşlı, Hüseyin Abdik, Fikrettin Şahin, Ezgi Avşar Abdik

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurochemical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Stem cell and gene therapies for leukodystrophies.Molecular therapy. Methods & clinical development · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Oğuz Kaan KırbaşDepartment of Genetics and Bioengineering, Faculty of Engineering and Architecture, Yeditepe University, Istanbul, 34755, Turkey.ORCID http://orcid.org/0000-0002-7510-474X
Batuhan Turhan BozkurtDepartment of Genetics and Bioengineering, Faculty of Engineering and Architecture, Yeditepe University, Istanbul, 34755, Turkey.ORCID https://orcid.org/0000-0003-1034-482X
Melis Rahime YıldırımDepartment of Genetics and Bioengineering, Faculty of Engineering and Architecture, Yeditepe University, Istanbul, 34755, Turkey.ORCID https://orcid.org/0000-0002-7539-1750
Pakize Neslihan TaşlıDepartment of Genetics and Bioengineering, Faculty of Engineering and Architecture, Yeditepe University, Istanbul, 34755, Turkey.ORCID https://orcid.org/0000-0002-0455-9894
Hüseyin AbdikDepartment of Molecular Biology and Genetics, Faculty of Engineering and Natural Sciences, İstanbul Sabahattin Zaim University, Istanbul, 34303, Turkey.ORCID https://orcid.org/0000-0003-3756-0645
Fikrettin ŞahinDepartment of Genetics and Bioengineering, Faculty of Engineering and Architecture, Yeditepe University, Istanbul, 34755, Turkey.ORCID https://orcid.org/0000-0002-7208-8967
Ezgi Avşar AbdikDepartment of Genomics, Faculty of Aquatic Sciences, Istanbul University, Istanbul, 34134, Turkey. e.avsarabdik@istanbul.edu.tr.ORCID https://orcid.org/0000-0003-0132-3234

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As an element of the cellular signaling systems, extracellular vesicles (EVs) exhibit many desirable traits for usage as targeted delivery vehicles. When administered, EVs cause little to no toxic or immune response, stay in circulation for longer periods compared to synthetic carriers, preferentially accumulate in tissues that are the same or similar to their cell-of-origin and can pass through the blood-brain barrier. Combined, these traits make neural EVs a particularly promising tool for delivering drugs to the brain. This study aims to combine tissue and EVs engineering to prepare neural differentiated cells derived EVs that exhibit neural properties, to develop an effective, tissue-homing drug and gene delivery platform for the brain. Early neural differentiated cell-derived EVs were produced with neural characteristics from neural differentiated human neonatal dermal fibroblasts. The EVs carried key neural proteins such as Nestin, Sox2 and Doublecortin. The cellular uptake of early neural differentiated cell-derived EVs was higher compared to non-neural EVs during in vitro uptake assays on neuroblastoma cells. Moreover, eND-EVs were significantly decreased the viability of neuroblastoma cells. In conclusion, this study revealed that early neural differentiated cell-derived EVs have potential as a promising drug carrier for the treatment of various neural disorders.

Indexed as

Extracellular VesiclesNeural Stem CellsNeuroblastomaCell DifferentiationCell Line, TumorCell SurvivalDrug Delivery SystemsFibroblastsHumansSOXB1 Transcription FactorsSOX2 protein, humanSOXB1 Transcription FactorsExtracellular vesiclesHuman neonatal dermal fibroblastsNeurogenic differentiationTargeted delivery

Identifiers

PMID38837091
PMCPMC11310242

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.